• OPEN AN ACCOUNT
Indian Indices
Sensex
73,123.83 -125.56
( -0.17%)
Global Indices
Nasdaq
52,230.09 -658.89
(-1.25%)
Dow Jones
7,644.13 -40.30
(-0.52%)
Hang Seng
62,584.98 -322.86
(-0.51%)
Nikkei 225
10,670.63 -54.40
(-0.51%)
Forex
USD-INR
94.61 0.10
(0.11%)
EUR-INR
106.18 0.08
(0.07%)
GBP-INR
126.70 0.19
(0.15%)
JPY-INR
0.60 0.00
(0.70%)

EQUITY - MARKET SCREENER

Tata Consumer Products Ltd
Industry :  Tea
BSE Code
ISIN Demat
Book Value()
500800
INE192A01025
179.9015397
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TATACONSUM
57.66
95011.01
EPS(TTM)
Face Value()
Div & Yield %
16.65
1
1.04
 

Caplin Point Laboratories' arm receives Form 483 with 10 observations from USFDA
Aug 22,2026
The inspection was carried out from 13 August 2026 to 21 August 2026. At the conclusion of the inspection, the company received Form 483 containing 10 observations.

The company said that the observations were procedural in nature and did not pertain to data integrity. It also stated that none of the observations were repeat observations.

Caplin Point Laboratories is a fully integrated pharmaceutical company with a strong presence in Latin America. The company’s consolidated net profit jumped 18.79% YoY to Rs 176.91 crore in Q1 FY27. Net sales increased 19.63% to Rs 610.36 crore in Q1 FY27 from Rs 510.22 crore in Q1 FY26.

The counter increased 1.09% to settle at Rs 2558.10 on Friday, 21 August 2026.